Skip to main content

Transgenomic Shares Jump 22 Percent After CEO Said Positive Cash Flow Likely

NEW YORK, July 13 (GenomeWeb News) - Shares in Transgenomic were up 22 percent, or $.17, at $.94 in late-afternoon trading after the company's CEO said the firm "should" reach neutral to positive operating cash flow by the end of the year.

 

Speaking to investors at Transgenomic's annual shareholder meeting today, Collin D'Silva said the company's recently completed restructuring will help the company "accelerate" revenue growth during the second half of the year, which he said would "approach" 20 percent on a year-over-year basis.

As GenomeWeb News reported last November, Transgenomic restructured its business and exited the oligonucleotide-manufacturing space in order to focus on its BioSystems segment.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.